Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Following radical prostatectomy (RP), about 20% to 40% of the patients with prostate cancer
(PCa) exhibit pathological parameters which are associated with a high risk of disease
recurrence. The rationale for NHT is based on the theory that androgen ablation induces PCa
apoptosis which induces a regression of the primary tumor bulk before RP. However the use of
NHT prior RP is highly controversial. In spite of these unenthusiastic results, the relative
short time of treatment and the use of different drugs from those utilized in other trials
might still to make this regimen attractive in terms of drug related side effects and
effectiveness. In this regard, Bicalutamide presents unique characteristics since it work
differently respect to other anti-hormonal agents by interfering on both genotropic and
non-genotropic mechanisms of androgen receptor